57 results
8-K
EX-10.1
ORKA
Oruka Therapeutics Inc.
4 Oct 24
Departure of Directors or Certain Officers
4:05pm
to ethics or workplace conduct.
“Change in Control” shall have the meaning set forth in the Company’s 2024 Stock Incentive Plan (or the meaning provided
8-K
EX-10.2
ORKA
Oruka Therapeutics Inc.
4 Oct 24
Departure of Directors or Certain Officers
4:05pm
or policies related to ethics or workplace conduct.
“Change in Control” shall have the meaning set forth in the Company’s 2024 Stock Incentive Plan
8-K
ORKA
Oruka Therapeutics Inc.
5 Sep 24
Oruka Therapeutics Announces Closing of Merger with ARCA biopharma and Previously Announced Private Placement of $275 Million
5:18pm
Amendments to the Registrant’s Code of Ethics, or Waiver of a Provision of the Code of Ethics.
On August 29, 2024, in connection with the Closing … , the Board adopted a new Code of Business Conduct and Ethics of the Company (the “Code of Conduct”), effective as of such date. The Code of Conduct
8-K
EX-14.1
ORKA
Oruka Therapeutics Inc.
5 Sep 24
Oruka Therapeutics Announces Closing of Merger with ARCA biopharma and Previously Announced Private Placement of $275 Million
5:18pm
Exhibit 14.1
Code of Business Conduct and Ethics
(August 29, 2024)
INTRODUCTION
This Code of Business Conduct and Ethics (this “Code”) provides … at public companies involving pervasive breakdowns in corporate ethics and internal controls over financial reporting. It was designed to rebuild
425
tvg9n7 pmh6is
3 Apr 24
Business combination disclosure
7:33am
8-K
EX-2.1
brgmao
3 Apr 24
ARCA biopharma and Oruka Therapeutics Announce Merger Agreement
7:31am